Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Metabolic vulnerability in NOTCH-driven T cell acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 535

Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK

Dr Etienne De Braekeleer talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about metabolic vulnerabilities that exist within NOTCH-driven T cell acute lymphoblastic leukaemia (ALL).

He explains the importance of using genome-wide CRISPR screens to identify new targets for relapsed and refractory ALL and more specifically, NOTCH-driven T-cell ALL.

Dr De Braekeleer discusses the role of NADK in this pathway and future efforts should be focused on elucidating the relationship between NOTCH and reduced ROS levels in ALL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation